PROFOUND MEDICAL CORP
PROFOUND MEDICAL CORP logo
PROF

PROFOUND MEDICAL CORP (PROF)

$6.32520.02%

Market is closed
– opens on 8 PM, 12 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$5.26
Day's Range
$6.35
$3.1
52-Week Range
$12.07
1 month return34.0%
3 month return16.7%
1 year return45.14%
5 year return35.98%

Company Information

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration ('FDA'). Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
OrganizationPROFOUND MEDICAL CORP
Employees146
CEODr. Arun Swarup Menawat MBA, Ph.D.
IndustryHealth Technology

Analyst Recommendation

based on 8 analysts ratings

Buy
87%
Buy
12%
Hold
0%
Sell

Based on 8 Wall street analysts offering stock ratings for PROFOUND MEDICAL CORP(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 110.43%

Current

$6.33

Target

$13.31

Recommendation Trend

Based on 8 analyst

Current1M Ago3M Ago
Buy
7
8
9
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
110.0M
Book Value
$2.88
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.53
Wall Street Target Price
13.31

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
1.83
Enterprise Value
65.0M
Enterprise Value/Revenue
10.13
Enterprise Value/Ebitda
-2.38

Technicals

Beta
1.84
50 Day MA
4.29
200 Day MA
6.88

Institutional Holdings

Gagnon Securities LLC

8.46%

Letko, Brosseau & Associates Inc

6.01%

Fidelity International Ltd

5.22%

Deerfield Management Co

3.51%

Gagnon Advisors, LLC

3.11%

Timelo Investment Management Inc.

3.06%

Discover more

Frequently Asked Questions

What is PROFOUND MEDICAL CORP share price today?

Can Indians buy PROFOUND MEDICAL CORP shares?

How can I buy PROFOUND MEDICAL CORP shares from India?

Can Fractional shares of PROFOUND MEDICAL CORP be purchased?

What are the documents required to start investing in PROFOUND MEDICAL CORP stocks?

What are today’s High and Low prices of PROFOUND MEDICAL CORP?

What are today’s traded volumes of PROFOUND MEDICAL CORP?

What is today’s market capitalisation of PROFOUND MEDICAL CORP?

What is the 52 Week High and Low Range of PROFOUND MEDICAL CORP?

How much percentage PROFOUND MEDICAL CORP is down from its 52 Week High?

How much percentage PROFOUND MEDICAL CORP is up from its 52 Week low?

What are the historical returns of PROFOUND MEDICAL CORP?

Who is the Chief Executive Officer (CEO) of PROFOUND MEDICAL CORP?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*